As part of the Phase 3 clinical trial, research participants with low-grade gliomas, taking the drug vorasidenib remained free from tumour re-growth for 27.7 months, as of the time of study read-out.
CIHR’s Centre for Research on Pandemic Preparedness and Health Emergencies is providing funding for eleven of the mpox projects, while the HIV/AIDS and Sexually Transmitted and Blood Borne Infections (STBBI) Research Initiative is funding two projects.